THE IMPACT OF COMBINED ADMINISTRATION OF SEROTONIN-SPECIFIC REUPTAKE INHIBITORS WITH ATORVASTATIN ON THE LIVER AND KIDNEYS . IN VITRO AND IN VIVO STUDIES